GENELINK GETS HIGHLY FAVORABLE REPORT!
November 1, 2001

Margate, NJ-(BUSINESS WIRE)-November 1, 2001 GeneLink BioSciences, Inc. (OTC:BB) The World's First Family Centered DNA Bank and Hereditary Genetic Information Service, announced today that Larry Oakley has recently published a highly favorable report on his Small-CapTrader.com web site. Mr. Oakley has been following the Company for well over a year and recently published several lengthy articles on the Company and its technology after talking with the Chairman and CEO, John R. DePhillipo. 

Mr. Oakley is quoted, "The appreciation potential here is exceptional." 

Oakley comments "A news release this morning [October 30,2001] announced that GNLK filed a patent application for a proprietary genetic test that predicts an individual's susceptibility to conditions that lead to accelerated skin aging & connective tissue breakdown. In this application, GNLK's oxidative stress profile not only measures an individual's inherent ability to defend against oxidative stress, it also examines a variant of this gene in which oxidative stress can greatly increase susceptibility to connective tissue breakdown & premature skin aging. 

"Consumers can be easily tested for GNLK's genetic variation by utilizing its patented simple non-invasive home kit & mailing it to one of their labs for evaluation. Based on GNLK's proprietary genetic test, specifically formulated skin care products that block oxidative stress can be used to reduce expression of this variant gene & retard skin aging. 

"The key here is that GNLK is collaborating with a major skin care formulator & raw ingredient supplier to produce products that alleviate oxidative stress & other age related deficiencies in the skin. On 9/19/2001, Arch Chemicals' (NYSE:ARJ) Personal Care Products Unit & GeneLink entered into a strategic partnership to develop such products based on a consumer's genetic makeup." 

Oakley concludes his article, "I see this association as the first of many. I suspect the next one will be with a large nutritional supplement corporation. The strategy is brilliant. GNLK can take advantage of the huge sales forces of its large partner corporations. GNLK will get a small portion of the selling price of the products sold as a result of its technology being used. The revenue potential to GNLK could be staggering." 

About GeneLink, Inc: GNLK is positioned to become a leading provider of genetic profiling technologies. It developed a proprietary method for "genetic profiling" (patents pending) and will begin licensing this breakthrough technology to companies that market or manufacture products for the $100 billion plus nutraceutical, skin care, wellness and weight-loss industries. GNLK has an FDA reviewed and patented non-invasive DNA Collection Kit®. Its DNA bank is located at the University of North Texas Health Science Center at Fort Worth, a 105year old medical facility that guarantees the DNA storage. 

Forward-Looking Statements: This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a new "safe harbor" for these types of statements.

SOURCE:GeneLink BioSciences, Inc.